ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Acceleron, Shire Ink Collaboration

by Rick Mullin
September 20, 2010 | APPEARED IN VOLUME 88, ISSUE 38

Acceleron Pharma and Shire have formed a joint development and commercialization agreement under which Shire will obtain rights outside the U.S. to a range of Acceleron molecules targeting activin receptor type IIB pathway, which helps regulate skeletal muscle growth. The collaboration will initially investigate ACE-031, currently in Phase II clinical trials for patients with Duchenne muscular dystrophy (DMD). Shire will make an up-front payment of $45 million to Acceleron, as well as possible milestone payments.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment